# Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma

> **NCT06071897** · PHASE3 · RECRUITING · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 15 (estimated)

## Conditions studied

- Neuroblastoma
- Ganglioneuroblastoma

## Interventions

- **DRUG:** monoclonal antibodies GD2

## Key facts

- **NCT ID:** NCT06071897
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06071897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06071897, "Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06071897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*